Targeted Oncology12h
Extended Follow-Up Bolsters Adjuvant Pembrolizumab DFS Rate in MIUC
Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant ...
Targeted Oncology13h
No Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer
The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...
Targeted Oncology13h
Maintenance Olaparib/Cediranib Fails to Extend PFS, OS in Ovarian Cancer
Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...
Targeted Oncology17h
NKT-2152: A Promising HIF-2α Inhibitor in ccRCC
0:09 | NKT-2152 is a HIF-2α inhibitor, so it will bind to HIF-2α to prevent heterodimerization with HIF-1 beta. And this is ...
Targeted Oncology14h
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...